According to the latest 13-F filing, legendary hedge fund manager Stanley Druckenmiller, through his family office, increased his stake in genetic testing company Natera (Nasdaq: NTRA), making it the largest holding in his U.S. listed equity portfolio, accounting for 18%. The analysis article notes that Natera's stock price has surged by nearly 100% over the past year, but its current price-to-sales ratio has reached 15x, significantly higher than the average for the U.S. stock market, reflecting investors' optimistic expectations for its growth prospects. Natera specializes in prenatal and cancer testing markets and has recently made progress in the organ donation testing business, with revenue growing by 39% year-over-year last quarter.